If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Issue of Equity - Replacement

7 Apr 2025 07:00

RNS Number : 8191D
Maven Income & Growth VCT 4 PLC
06 April 2025
 

Maven Income and Growth VCT 4 PLC (the Company)

 

Issue of Equity - Replacement announcement

 

The issuer advises of an amendment to the Issue of Equity announcement and that the following replaces the Maven Income and Growth VCT 4 PLC announcement released at 18.18 BST on 4 April 2025 under RNS No. 8096D.

 

The reference to the total amount of valid applications has been amended to £2,044,066; the total number of shares issued has been amended to 3,338,726; the range of offer prices at which the shares were issued has been amended to 59.47p to 61.05p per Ordinary Share; and the Ordinary Shares now in issue, and the total voting rights, have been amended to 154,982,952. All other details remain unchanged.

 

The full amended version is shown below.

 

Maven Income and Growth VCT 4 PLC (the Company)

 

Issue of Equity

 

On 27 September 2024, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to £5 million, with an over-allotment facility for up to a further £5 million (the Offer). As announced on 1 April 2025, the Company's Offer is now fully subscribed and closed to further applications.

 

Pursuant to the Offer, £2,044,066 of valid applications were received in the period from 9.00am on 24 March 2025 up to and including 9.00am on 1 April 2025 in respect of the 2024/2025 tax year. As a result, the Company has issued and allotted 3,338,726 new Ordinary Shares on 4 April 2025. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which the shares were issued were in the range of 59.47p to 61.05p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 154,982,952. Therefore, the total number of voting rights in the Company is 154,982,952 and this may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

In respect of this allotment, an application will be made by the Company to the FCA and to the London Stock Exchange for the new Ordinary Shares to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective, and dealings will commence, on or around 9 April 2025.

 

This is the fourth and final allotment in respect of 2024/2025 tax year. It is intended that an allotment in respect of applications for the 2025/2026 tax year will take place on, or before, 2 May 2025.

 

For further information, please contact:

 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Maven Capital Partners UK LLP

Secretary

 

4 April 2025

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESSAFFMEISESL
Date   Source Headline
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:18 pmRNSIssue of Equity
2nd Apr 20255:58 pmRNSAnnual Financial Report
1st Apr 20255:05 pmRNSDirectorate Change
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:12 pmRNSDirector/PDMR Shareholding
27th Mar 20251:07 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
18th Mar 20254:10 pmRNSTransaction in Own Shares
14th Mar 202511:58 amRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:20 amRNSDirector/PDMR Shareholding
19th Feb 202510:19 amRNSDirector/PDMR Shareholding
19th Feb 202510:18 amRNSDirector/PDMR Shareholding
19th Feb 202510:11 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
28th Jan 202510:42 amRNSIssue of Equity
24th Jan 202511:34 amRNSNet Asset Value(s)
27th Dec 20249:21 amRNSDirector Declaration
10th Dec 20244:08 pmRNSTransaction in Own Shares
26th Nov 20244:20 pmRNSNet Asset Value(s)
14th Nov 20242:55 pmRNSResult of General Meeting
18th Oct 20249:33 amRNSDirector/PDMR Shareholding
18th Oct 20249:29 amRNSIssue of Equity
15th Oct 20249:06 amRNSStatement re Dividend Investment Scheme
27th Sep 20244:31 pmRNSPublication of a Prospectus
18th Sep 202411:09 amRNSHalf-year Report
2nd Sep 20244:55 pmRNSTransaction in Own Shares
23rd Aug 20242:52 pmRNSStatement re NAV and Interim Dividend
24th May 202410:02 amRNSDirector/PDMR Shareholding
24th May 20249:58 amRNSIssue of Equity - Dividend Investment Scheme
15th May 20244:18 pmRNSTransaction in Own Shares
15th May 20242:17 pmRNSNet Asset Value - Dividend Investment Scheme
9th May 20242:35 pmRNSResult of AGM
9th May 20242:28 pmRNSUnaudited Net Asset Value
1st May 202410:08 amRNSIssue of Equity
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:48 pmRNSIssue of Equity
27th Mar 202410:39 amRNSIssue of Equity
25th Mar 202410:14 amRNSStatement re Offer for Subscription
19th Mar 20245:03 pmRNSTransaction in Own Shares
20th Feb 20242:48 pmRNSDividend Declaration
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:10 amRNSIssue of Equity
17th Jan 202410:03 amRNSDirector/PDMR Shareholding
17th Jan 202410:02 amRNSDirector/PDMR Shareholding
17th Jan 20249:58 amRNSIssue of Equity
15th Jan 20244:28 pmRNSUnaudited Net Value Asset
15th Nov 20235:06 pmRNSTransaction in Own Shares
9th Nov 20233:53 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.